[HTML][HTML] Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
[HTML][HTML] Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
CJ Nederpelt, L Naar, KW Sylvester… - … of Thrombosis and …, 2020 - ncbi.nlm.nih.gov
Methods Consecutive patients who received andexanet alfa for reversal of FXa inhibitor‐
associated extracranial hemorrhage were identified. The primary outcome of interest was …
associated extracranial hemorrhage were identified. The primary outcome of interest was …
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
CJ Nederpelt, L Naar, KW Sylvester… - … of Thrombosis and …, 2020 - europepmc.org
Methods Consecutive patients who received andexanet alfa for reversal of FXa inhibitor-
associated extracranial hemorrhage were identified. The primary outcome of interest was …
associated extracranial hemorrhage were identified. The primary outcome of interest was …
Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
CJ Nederpelt, L Naar, KW Sylvester… - Journal of Thrombosis …, 2020 - jthjournal.org
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa
CJ Nederpelt, L Naar, KW Sylvester… - … of thrombosis and …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
CJ Nederpelt, L Naar, KW Sylvester… - … of Thrombosis and …, 2020 - Wiley Online Library
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
[引用][C] Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa
CJ Nederpelt, L Naar… - Journal of …, 2020 - lomalinda.elsevierpure.com
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet
alfa — Faculty Research (Pure) - Loma Linda University Skip to main navigation Skip to search …
alfa — Faculty Research (Pure) - Loma Linda University Skip to main navigation Skip to search …